Press coverage about Achillion Pharmaceuticals (NASDAQ:ACHN) has been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.8016089984357 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
ACHN has been the topic of a number of recent research reports. Zacks Investment Research raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, February 27th. BidaskClub raised Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 6th. ValuEngine raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Finally, Barclays raised Achillion Pharmaceuticals from an “underweight” rating to an “equal weight” rating and set a $5.00 target price on the stock in a report on Monday, May 21st. One analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $4.88.
Shares of Achillion Pharmaceuticals stock opened at $2.84 on Friday. The company has a market capitalization of $391.50 million, a PE ratio of -4.58 and a beta of 0.86. Achillion Pharmaceuticals has a one year low of $2.58 and a one year high of $5.66.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.01). research analysts forecast that Achillion Pharmaceuticals will post -0.56 earnings per share for the current year.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.